Spectrum Settles Cancer Drug Patent Row With Fresenius
Spectrum Pharmaceuticals said Wednesday that it had reached a settlement with Fresenius Kabi in a Delaware federal suit accusing it of infringing three patents for its cancer drug Folotyn, after reaching...To view the full article, register now.
Already a subscriber? Click here to view full article